Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (January 2005)
22 slides from Pharmacopeia's investor presentation, Jan 10, 2005

Slide 1: New Opportunity
PHARMACOPEIA DRUG DISCOVERY New Opportunity Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics for significant unmet medical needs 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 2: Strategic Value Capture Points
Strategic Value Capture Points Hi Market Value products Lo Lo Investment (Time, $, IP) 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 3: Intellectual Capital and Experience
Over 160/patents filed with 69 issued + Chemistry - 92 + Biology = 29 + Engineering - 36 ° Software -5 160 Employees (140 scientists) + Chemistry - 80 + Biology - 40 + Engineering & Informatics - 20 + General & Administrative - 20 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 4: Drug Discovery Capabilities
Drug Discovery Capabilities Assay Development Medicinal Chemistr omputational ia brug bi Pharmacopeia Drug Discovery ‘Compound. and Development Collection Pharmacology 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 5: Recent Collaboration Milestones
9/27/04 Pharmacopeia Delivers Leads and Triggers Research Milestone in Collaboration with Neurocrine 10/5/04 Pharmacopeia Achieves Preclinical Development Candidate Milestone in Collaboration with Schering-Plough 10/26/04 Biovitrum AB and Pharmacopeia Form Strategic Research Alliance 4U3009510 9NuG

Slide 6: Strategy
Strategy Generate maximum return on the existing asset base in the near-term, whilst offering greater future returns on investments being made at Pharmacopeia today © Advance and expand the portfolio of wholly-owned therapeutic product programs ° Evolve the successful collaborative drug discovery bu

Slide 7: Raise Pharmacopeia profile
Raise Pharmacopeia profile Maintain existing business Build the internal portfolio Sow seeds for future growth Focus Communicate the opportunity Evolve the collaboration model Retain to clinical Phase II Build in immunobiology 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 8: Rheumatoid Arthritis / Psoriasis
Rheumatoid Arthritis / Disease ne drug modulates underlying mul Psoriasis le process eases 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 9: Business Evolution
PHARMACOPEIA DRUG DISCOVERY January 2005 Business Evolution

Slide 10: Robust Pipeline
Robust Pipeline In Vitro Lead Optimization ©) In Clinical Trials w/ Collaborators 4 Lead Discovery 20+ 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 11: Research & Development Product Portfolio
Research & Development Product Portfolio Pssieaos Psaoanes Peta pszatez2 Pseoange Pseott6a porrenaa pssrares Internal Programs Pseneso4 pscoenze Poezeaor Fredinioal nies Phase Lead Program | Partner Gansctton OFfimization Development | 1 i Bheunatid — orto ye A | amiss su ‘Asthmallleigy Daiichi Vad

Slide 12: p38 MAP Kinase Inhibition
p38 MAP Kinase Inhibition * P38 is a member of the MAP kinase superfamily * Independent activation pathway responsive to stress stimuli: — inflammatory cytokines, endotoxin, osmotic, UV, chemical stress * Regulates production of inflammatory cytokines — TNF-«, IL-1, IL-6, IL-8 4U3009510 9NuG gage bi

Slide 13: P38 kinase: Central Role in Inflammation
P38 kinase: Central Role in Inflammation RA — anti-TNFo Enbrel RA - anti IL-1 Remicade Humira Kineret Blocks the inflammatory effects of TNF & IL-1 PS 516895 in clinical Phase | 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 14: Mechanism of Action
Mechanism of Action Reversible in| r unlike BIRB-796 CNS Safety No CNS penetration compared to VX-745 Liver Safety Superior CYP profile to Phil candidates Specificity for p38 il ity for diminished off-target effects Efficacy Efficacious at very low doses 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aie

Slide 15: Molecular Basis of Angiogenesis
Molecular Basis of Angiogenesis A @ Angiogenic @ EC receptor binding “~~ factorproduction Pi icasc... intracellular signaling @ EC activation BM degradation EC proliferation © Directional ~ migration Femcoth muscle cal @ ECM remodeling ® Tube formation ® Loop formation ® Vascular stabilization Angio

Slide 16: Physiology and Pathology of avB3
1. 2. Physiology and Pathology of avB3 Role in Angiogenesis avp3 is expressed on i. retinal vasculature of patients with Age-related Macular Degeneration (AMD) ii. vascular endothelial cells from patients with Proliferative Diabetic Retinopathy (PDR) avp3 expression is linked to neoplastic progressi

Slide 17: Pharmacopeia Drug Discovery
ray PHARMACOPEIA DRUG DISCOVERY January 2005 qui ‘UoNeZUeINISeACeN jo ealy

Slide 18: PS388023 inhibits retinal neovascularization
PS388023 inhibits retinal neovascularization Vehicle cRGD PS$388023 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 19: The Next Months
The Next 12 months Continuing milestone flow from collaborations Expanded product portfolio Partnered programs should advance Addition of key pre-clinical and clinical assets Internal programs towards preclinical development 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 20: ly product |
ly product | eston + Intelle

Slide 21: Financial Summary
Financial Summary $24-28MM in revenues for 2004 $40MM in cash 12.3 million shares 52 week range $4.46 - $10.35 (currently $5-6) Market Cap = ~ $70MM Enterprise value = ~ $30MM 4U3009510 9NuG gage bisdO2BWEOHd Gee $002 Aienuer

Slide 22: Searchable
Searchable text section of graphics shown above January 2005 [ LOG O] New Opportunity Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics for significant unmet medical needs Str ategic Value Capture Points [CHART] [ GRA PHIC] I
Source: SEC EDGAR · 8-K filed Jan 10, 2005
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008